The blockade of immune checkpoints in cancer immunotherapy

Pardoll, Drew M.·2012·Nature Reviews Cancer

DOI 10.1038/nrc3239

Cited by (1,126)

Items 601–700 of 1,126

Molecular and nanoengineering approaches towards activatable cancer immunotherapy
Chi Zhang, Kanyi Pu · 2020 · Chemical Society Reviews
NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion
Hongwei Lv, Guishuai Lv, Cian Chen, Qianni Zong, Guo‐Qing Jiang, Dan Ye, Xiuliang Cui, Yufei He, Wei Xiang, Qin You Han et al. · 2020 · Cell Metabolism
Exploiting replicative stress to treat cancer
Matthias Dobbelstein, Claus Storgaard Sørensen · 2015 · Nature Reviews Drug Discovery
Tailoring Nanomaterials for Targeting Tumor‐Associated Macrophages
Muhammad Ovais, Mengyu Guo, Chunying Chen · 2019 · Advanced Materials
Metalloimmunology: The metal ion-controlled immunity
Chenguang Wang, Rui Zhang, Xiaoming Wei, Mengze Lv, Zhengfan Jiang · 2019 · Advances in immunology
TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma
Guillerey, Camille, Harjunpää, Heidi, Carrié, Nadège, Kassem, Sahar, Teo, Tricia, Miles, Kim, Krumeich, Sophie, Weulersse, Marianne, Cuisinier, Marine, Stannard, Kimberley et al. · 2018 · Blood
Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer
Xiaomei Gong, Xuefei Li, Tao Jiang, Huikang Xie, Zhengfei Zhu, Fei Zhou, Caicun Zhou · 2017 · Journal of Thoracic Oncology
Self-Supplied Tumor Oxygenation through Separated Liposomal Delivery of H2O2 and Catalase for Enhanced Radio-Immunotherapy of Cancer
Xuejiao Song, Jun Xu, Chao Liang, Yu Chao, Qiutong Jin, Chao Wang, Meiwan Chen, Zhuang Liu · 2018 · Nano Letters
VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance
Mohamed A. ElTanbouly, Yanding Zhao, Elizabeth C. Nowak, Jiannan Li, Evelien Schaafsma, Isabelle Le Mercier, Sabrina Ceeraz, Janet Louise Lines, Changwei Peng, Catherine Carrière et al. · 2020 · Science
Advances in cancer immunotherapy: historical perspectives, current developments, and future directions
Mei‐Yin Zhang, Chao-jun Liu, Jing Tu, Min Tang, Milad Ashrafizadeh, Noushin Nabavi, Gautam Sethi, Peiqing Zhao, Shijian Liu · 2025 · Molecular Cancer
A snapshot of the PD-1/PD-L1 pathway
Chinmoy Ghosh, Gary Luong, Yue Sun · 2021 · Journal of Cancer
T cell differentiation in chronic infection and cancer: functional adaptation or exhaustion?
Daniel E. Speiser, Daniel T. Utzschneider, Susanne G. Oberle, Christian Münz, Pedro J. Romero, Dietmar Zehn · 2014 · Nature reviews. Immunology
Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non–Small Cell Lung Cancer
Khorrami, Mohammadhadi, Prasanna, Prateek, Gupta, Amit, Patil, Pradnya, Velu, Priya D., Thawani, Rajat, Corredor, German, Alilou, Mehdi, Bera, Kaustav, Fu, Pingfu et al. · 2020 · Cancer Immunology Research
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Choueiri, Toni K., Fishman, Mayer N., Escudier, Bernard, McDermott, David F., Drake, Charles G., Kluger, Harriet, Stadler, Walter M., Perez-Gracia, Jose Luis, McNeel, Douglas G., Curti, Brendan et al. · 2016 · Clinical Cancer Research
Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy
Paula D. Bos, George Plitas, Dipayan Rudra, Sue Y. Lee, Alexander Yu Rudensky · 2013 · The Journal of Experimental Medicine
A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model
Tomomi Nakayama Iwata, Chiaki Ishii, Saori Ishida, Yusuke Ogitani, Teiji Wada, Toshinori Agatsuma · 2018 · Molecular Cancer Therapeutics
A review of glioblastoma immunotherapy
Ravi Teja Medikonda, Gavin P. Dunn, Maryam Rahman, Peter Edward Fecci, Michael K. Lim · 2020 · Journal of Neuro-Oncology
Overview of the application of inorganic nanomaterials in cancer photothermal therapy
Natanael F. Fernandes, Carolina F. Rodrigues, André Ferreira Moreira, Ilídio Joaquim Correia · 2020 · Biomaterials Science
β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy
Bucsek, Mark J., Qiao, Guanxi, MacDonald, Cameron R., Giridharan, Thejaswini, Evans, Lauren, Niedzwecki, Brian, Liu, Haichao, Kokolus, Kathleen M., Eng, Jason W.-L., Messmer, Michelle N. et al. · 2017 · Cancer Research
Biology and Management of Patients With Triple-Negative Breast Cancer
Sharma, Priyanka · 2016 · The Oncologist
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma
Nan Chen, Wenfeng Fang, Lin Zhong, Peijian Peng, Juan Wang, Jianhua Zhan, Shaodong Hong, Jiaxing Huang, Lin Liu, Jin Sheng et al. · 2017 · Cancer Immunology Immunotherapy
Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H. O’Neil, John M. Wallmark, David Lorente, Elena Élez, Judith Raimbourg, Carlos Gomez‐Roca, Samuel Ejadi, Sarina Anne Piha-Paul, Mark N. Stein, Albiruni R. Abdul Razak et al. · 2017 · PLoS ONE
Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice
Yushu Joy Xie, Michael Lawrence Dougan, Noor Jailkhani, Jessica R. Ingram, Tao Fang, Laura Kummer, Noor Momin, Novalia Pishesha, Steffen Rickelt, Richard O. Hynes et al. · 2019 · Proceedings of the National Academy of Sciences
Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma
Bruno Sangro, Stephen Lam Chan, Tim Meyer, María Reig, Anthony B. El-Khoueiry, Peter Robert Galle · 2020 · Journal of Hepatology
EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss
John Howard Sampson, Bryan D. Choi, Luis A Sanchez-Perez, Carter M. Suryadevara, David J. Snyder, Catherine Flores, Robert J. Schmittling, Smita K. Nair, Elizabeth A. Reap, Pamela K. Norberg et al. · 2013 · Clinical Cancer Research
Concise Review: Cancer Cells, Cancer Stem Cells, and Mesenchymal Stem Cells: Influence in Cancer Development
Federica Papaccio, Francesca Paino, Tarik Regad, Gianpaolo Papaccio, Vincenzo Desiderio, Virginia Tirino · 2017 · Stem Cells Translational Medicine
Targeted and Immune-Based Therapies for Hepatocellular Carcinoma
Tim F. Greten, Chunwei Walter Lai, Guangfu Li, Kevin F. Staveley-O’Carroll · 2018 · Gastroenterology
NIR‐Triggered Phototherapy and Immunotherapy via an Antigen‐Capturing Nanoplatform for Metastatic Cancer Treatment
Meng Wang, Jun Song, Feifan Zhou, Ashley R. Hoover, Cynthia K. Murray, Benqing Zhou, Lu Wang, Junle Qu, Wei R. Chen · 2019 · Advanced Science
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
Saleh, Reem, Elkord, Eyad · 2020 · Seminars in Cancer Biology
Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy
Marie‐Claude Bourgeois‐Daigneault, Dominic Guy Roy, Amelia Sadie Aitken, Nader El-Sayes, Nikolas Tim Martin, Oliver Varette, Theresa J. Falls, Lauren Elizabeth St-Germain, Adrian Pelin, Brian Dennis Lichty et al. · 2018 · Science Translational Medicine
miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint
Shaohua Xu, Zhen Tao, Bo Hai, Huagen Liang, Ying Qiang Shi, Tao Wang, Wen Song, Yong Chen, Jun Ouyang, Jinhong Chen et al. · 2016 · Nature Communications
Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management
Mario Sznol, Michael Andrew Postow, Marianne J Davies, Anna C. Pavlick, Elizabeth R. Plimack, Montaser F. Shaheen, Colleen Veloski, Caroline Robert · 2017 · Cancer Treatment Reviews
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Luisa Barrueto, Francheska Caminero, Lindsay Cash, Courtney Makris, Purushottam Lamichhane, Rahul R. Deshmukh · 2020 · Translational Oncology
Immunotherapy, Inflammation and Colorectal Cancer
Charles Robert Lichtenstern, Rachael Katie Ngu, Shabnam Shalapour, Michael Karin · 2020 · Cells
Pembrolizumab for the treatment of non-small cell lung cancer
Sung Hee Lim, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn · 2016 · Expert Opinion on Biological Therapy
PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes
Matthew W. Rosenbaum, Jacob R. Bledsoe, Vicente Morales‐Oyarvide, Tiffany G. Huynh, Mari A. Mino-Kenudson · 2016 · Modern Pathology
Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy
Jung-Mao Hsu, Chia‐Wei Li, Yun‐Ju Lai, Mien‐Chie Hung · 2018 · Cancer Research
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Ju‐Yeun Lee, Hyun Tae Lee, Woori Shin, Jongseok Chae, Jaemo Choi, Sung Hyun Kim, Heejin Lim, Tae Won Heo, Kyeong Young Park, Yeon Ji Lee et al. · 2016 · Nature Communications
Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook
Chao Wang, Yanqi Ye, Quanyin Hu, Adriano Bellotti, Zhen Gu · 2017 · Advanced Materials
TGFβ1-Mediated SMAD3 Enhances PD-1 Expression on Antigen-Specific T Cells in Cancer
Park, Benjamin V., Freeman, Zachary T., Ghasemzadeh, Ali, Chattergoon, Michael A., Rutebemberwa, Alleluiah, Steigner, Jordana, Winter, Matthew E., Huynh, Thanh V., Sebald, Suzanne M., Lee, Se-Jin et al. · 2016 · Cancer Discovery
Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
Ching‐Yao Yang, Mong‐Wei Lin, Yih‐Leong Chang, Chen‐Tu Wu, Pan‐Chyr Yang · 2014 · European Journal of Cancer
A proteomic landscape of diffuse-type gastric cancer
Sai Ge, Xia Xia, Chen Ding, Bei Zhen, Quan Zhou, Jinwen Feng, Jiajia Yuan, Rui Chen, Yumei Li, Zhongqi Ge et al. · 2018 · Nature Communications
Tumor Suppressor miRNA in Cancer Cells and the Tumor Microenvironment: Mechanism of Deregulation and Clinical Implications
Khalid Otmani, Philippe Lewalle · 2021 · Frontiers in Oncology
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Tomoe Higuchi, Dallas B. Flies, Nicole A. Marjon, Gina M. Mantia-Smaldone, Lukas Ronner, Phyllis A. Gimotty, Sarah Foster Adams · 2015 · Cancer Immunology Research
The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies
Jan A. Burger, John G. Gribben · 2013 · Seminars in Cancer Biology
Pathogenesis beyond the cancer clone(s) in multiple myeloma
Giada Bianchi, Nikhil C. Munshi · 2015 · Blood
Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients
Hyun-Bae Jie, Neil Gildener‐Leapman, Jing Li, Raghvendra Mohan Srivastava, Sandra Poveda Gibson, Theresa L. Whiteside, RL Ferris · 2013 · British Journal of Cancer
Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge
Amani Makkouk, George J. Weiner · 2014 · Cancer Research
Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
Liting Guo, Haijun Zhang, Baoan Chen · 2017 · Journal of Cancer
Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028
Andréa Varga, Sarina Anne Piha-Paul, Patrick Alexander Ott, Janice M. Mehnert, Dominique Berton-Rigaud, Anne Morosky, Ping Yang, Jane I. Ruman, Daniela Elena Matei · 2018 · Gynecologic Oncology
Phage display screening of therapeutic peptide for cancer targeting and therapy
Phei Er Saw, Erwei Song · 2019 · Protein & Cell
Activating Macrophage‐Mediated Cancer Immunotherapy by Genetically Edited Nanoparticles
Lang Rao, Shukun Zhao, Churan Wen, Rui Tian, Lisen Lin, Bo Cai, Yue Sun, Fei Kang, Zhèn Yáng, Liangcan He et al. · 2020 · Advanced Materials
CTLA-4 and PD-L1 Checkpoint Blockade Enhances Oncolytic Measles Virus Therapy
Christine E. Engeland, Christian Grossardt, Rūta Veinalde, Sascha Bossow, Diana Lutz, Johanna K. Kaufmann, Ivan Shevchenko, Viktor Umansky, Dirk M. Nettelbeck, Wilko Weichert et al. · 2014 · Molecular Therapy
Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade
Valerie Lee, Adrian Gerard Murphy, Dung Thi Le, Luis Alberto Diaz · 2016 · The Oncologist
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
Chiara Nicolazzo, Cristina Raimondi, Marialaura Mancini, S Caponnetto, Angela Gradilone, Orietta Gandini, Maria Mastromartino, Gabriella Del Bene, Alessandra Anna Prete, Flavia Longo et al. · 2016 · Scientific Reports
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
Antonio Lopez-beltran B, Alessia Cimadamore, Ana Blanca, Francesco Massari, Nuno Vau, Marina Scarpelli, Liang Cheng C, Rodolfo Montironi · 2021 · Cancers
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies
Holbrook E K Kohrt, Ariane Thielens, Aurélien Marabelle, Idit Sagiv-Barfi, Caroline Sola, Fabien Chanuc, Nicolas Fuséri, Cécile Bonnafous, Debra Katherine Czerwinski, Amanda Rajapaksa et al. · 2013 · Blood
Cancer Cell Membrane-Coated Nanoparticles for Cancer Management
Jenna C. Harris, Mackenzie A. Scully, Emily S. Day · 2019 · Cancers
Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy
Filippo Galli, Jesus Vera Aguilera, Belinda Palermo, Svetomir N. Markovic, Paola Nisticò, Alberto Signore · 2020 · Journal of Experimental & Clinical Cancer Research
Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities
Pauken, Kristen E., Dougan, Michael, Rose, Noel R., Lichtman, Andrew H., Sharpe, Arlene H. · 2019 · Trends in Immunology
AP-1 Transcription Factors as Regulators of Immune Responses in Cancer
Vassilios Atsaves, Vasiliki Leventaki, George Z. Rassidakis, Francois X. Claret · 2019 · Cancers
EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment
Alina Nicolae, Stefania Pittaluga, Shahed Azzam Ahmed Abdullah, Seth M. Steinberg, Thu Pham, Theresa M. DAVIES-HILL, Liqiang Xi, Mark A. Raffeld, Elaine S. Jaffe · 2015 · Blood
Antitumour immunity regulated by aberrant ERBB family signalling
Shogo Kumagai, Shohei Koyama, Hiroyoshi Nishikawa · 2021 · Nature reviews. Cancer
Low-Temperature Photothermal Therapy: Strategies and Applications
Xiulin Yi, Qiu‐Yi Duan, Fu‐Gen Wu · 2021 · Research
Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: ‘What does not kill me strengthens me’
Angela Oliveira Pisco, Sui Huang · 2015 · British Journal of Cancer
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Somayeh Vafaei, Angelina Olegovna Zekiy, Ramadhan Ado Khanamir, Burhan Abdullah Zaman, Arman Ghayourvahdat, Hannaneh Azimizonuzi, Majid Zamani · 2022 · Cancer Cell International
Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
Abhishek Dinkarnath Garg, Sanket More, Nicole Rufo, Odeta Meçe, Maria Livia Sassano, Patrizia Agostinis, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi · 2017 · OncoImmunology
Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion
Frangieh, Chris J., Melms, Johannes C., Thakore, Pratiksha I., Geiger-Schuller, Kathryn R., Ho, Patricia, Luoma, Adrienne M., Cleary, Brian, Jerby-Arnon, Livnat, Malu, Shruti, Cuoco, Michael S. et al. · 2021 · Nature Genetics
Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy
Guojun Chen, Zhitong Chen, Di Wen, Zejun Wang, Hongjun Li, Yi Zeng, Gianpietro Dotti, Richard E. Wirz, Zhen Gu · 2020 · Proceedings of the National Academy of Sciences
Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells
Annie A. Wu, Virginia E. Drake, Huai-Shiuan Huang, ShihChi Chiu, Lei Zheng · 2015 · OncoImmunology
Myeloid-Derived Suppressor Cells Endow Stem-like Qualities to Breast Cancer Cells through IL6/STAT3 and NO/NOTCH Cross-talk Signaling
Dongjun Peng, Takashi Tanikawa, Wei Li, Lili Zhao, Linda Vatan, Wojciech Szeliga, Shanshan Wan, Shuang Wei, Yin Wang, Yan Liu et al. · 2016 · Cancer Research
Multifunctional phototheranostic nanomedicine for cancer imaging and treatment
Di Gao, X. Guo, Xingcai Zhang, Shaokui Chen, Ying Wang, Taojia Chen, Guan J. Huang, Yan feng Gao, Zhongmin Tian, Zhe Yang · 2019 · Materials Today Bio
Unravelling the Interplay between Extracellular Acidosis and Immune Cells
Fernando A. Erra Díaz, Ezequiel Dantas, Jorge Raul Geffner · 2018 · Mediators of Inflammation
Nanoscale coordination polymers induce immunogenic cell death by amplifying radiation therapy mediated oxidative stress
Zhusheng Huang, Yuxiang Wang, Dan Yao, Jinhui Wu, Yiqiao Hu, Ahu Yuan · 2021 · Nature Communications
Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer
Moumita Kundu, Ramesh Butti, Venketesh K. Panda, Diksha Malhotra, Sumit Das, Tandrima Mitra, Prachi Kapse, Suresh Gosavi, Gopal C. Kundu · 2024 · Molecular Cancer
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Funda Meric‐Bernstam, Randy F. Sweis, Stefan Kasper, Omid Hamid, Shailender Bhatia, Reinhard Dummer, Agostina Stradella, Georgina Venetia Long, Anna Spreafico, Toshio Shimizu et al. · 2022 · Clinical Cancer Research
Immune system and melanoma biology: a balance between immunosurveillance and immune escape
Anna Maria Passarelli, Francesco Mannavola, Luigia Stefania Stucci, Marco Tucci, Francesco Silvestris · 2017 · Oncotarget
Smart Injectable Hydrogels for Cancer Immunotherapy
Yu Chao, Qian Chen, Zhuang Liu · 2019 · Advanced Functional Materials
How to select IgG subclasses in developing anti-tumor therapeutic antibodies
Jifeng Yu, Yongping Song, Wenzhi Tian · 2020 · Journal of Hematology & Oncology
The Non–Small Cell Lung Cancer Immune Contexture. A Major Determinant of Tumor Characteristics and Patient Outcome
Romain Remark, Christian Becker, Jorge E Gomez, Diane Damotte, Marie‐Caroline Dieu‐Nosjean, Catherine Sautès‐Fridman, Wolf H. Fridman, Charles A. Powell, Nasser Khaled Altorki, Miriam Mérad et al. · 2014 · American Journal of Respiratory and Critical Care Medicine
PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer
Nisha Nagarsheth, Dongjun Peng, Ilona Kryczek, Ke Wu, Wei Li, Ende Zhao, Lili Zhao, Shuang Wei, Timothy L. Frankel, Linda Vatan et al. · 2015 · Cancer Research
Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti-PD-1 resistance in head and neck cancer
Zhou, Liye, Mudianto, Tenny, Ma, Xiaojing, Riley, Rachel, Uppaluri, Ravindra · 2020 · Clinical Cancer Research
Host immunity contributes to the anti-melanoma activity of BRAF inhibitors
Deborah A. Knight, Shin Foong Ngiow, Ming Li, Tiffany J. Parmenter, Stephen Mok, Ashley A. Cass, Nicole M. Haynes, Kathryn M. Kinross, Hideo Yagita∥, Richard Chikara Koya et al. · 2013 · Journal of Clinical Investigation · Retracted
CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes
Moritz Rapp, Maximilian W. M. Wintergerst, Wolfgang Gerhard Kunz, Viola Katharina Vetter, Maximilian M. L. Knott, Dominik Lisowski, Sascha Haubner, Stefan Moder, Raffael Thaler, Stephan Eiber et al. · 2019 · The Journal of Experimental Medicine
Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors
Lihong Peng, Yong Wang, Fen Liu, Xiaotong Qiu, Xinwei Zhang, Fang Chen, Xiaoyin Qian, Yong Li · 2020 · Cancer Immunology Immunotherapy
Computational genomics tools for dissecting tumour–immune cell interactions
Hubert Hackl, Pornpimol Charoentong, Francesca Finotello, Zlatko Trajanoski · 2016 · Nature Reviews Genetics
Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Dung Thi Le, Vincent J. Picozzi, Andrew H. Ko, Zev A. Wainberg, Hedy Lee Kindler, Andrea Wang‐Gillam, Paul E. Oberstein, Michael Andrew Morse, Herbert J. Zeh, Colin D. Weekes et al. · 2019 · Clinical Cancer Research
Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy
Gi‐Hoon Nam, Yoonjeong Choi, Gi Beom Kim, Seohyun Kim, Seong A Kim, In‐San Kim · 2020 · Advanced Materials
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
Kun Pang, Zhenduo Shi, Liuya Wei, Dong Fang Yang, Yu-Yang Ma, Wei Wang, Guang-Yue Wang, Ming-Yang Cao, Jiajun Dong, Yu-Ang Chen et al. · 2022 · Drug Resistance Updates
3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade
Aref, Amir R., Campisi, Marco, Ivanova, Elena, Portell, Andrew, Larios, Dalia, Piel, Brandon P., Mathur, Natasha, Zhou, Chensheng, Coakley, Raven Vlahos, Bartels, Alan et al. · 2018 · Lab on a Chip
Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models
Seiji Okada, Kulthida Vaeteewoottacharn, Ryusho Kariya · 2019 · Cells
Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity
Sushrut Kamerkar, Charan Leng, Olga V. Burenkova, Su Chul Jang, Christine McCoy, Kelvin Xi Zhang, Kevin Dooley, Samuel Kasera, Tong Zi, Sílvia Sisó et al. · 2022 · Science Advances
Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients
Peters, Brandilyn A., Wilson, Melissa, Moran, Una, Pavlick, Anna, Izsak, Allison, Wechter, Todd, Weber, Jeffrey S., Osman, Iman, Ahn, Jiyoung · 2019 · Genome Medicine
EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape
Seung‐Oe Lim, Chia‐Wei Li, Weiya Xia, Heng‐Huan Lee, Shih-Shin Chang, Jia Shen, Jennifer L. Hsu, Daniel Raftery, Danijel Djukovic, Haiwei Gu et al. · 2016 · Cancer Research
Enterocolitis due to immune checkpoint inhibitors: a systematic review
Émilie Soularue, Patricia Lepage, Jean Frédéric Colombel, Clélia Coutzac, David M. Faleck, Lysiane Marthey, Michael Collins, Nathalie Chaput, Caroline Robert, Franck Carbonnel · 2018 · Gut
FDG PET/CT for assessing tumour response to immunotherapy
Nicolas Aide, Rodney J. Hicks, Christophe Le Tourneau, Stéphanie Lheureux, Stefano Fanti, Egesta Lopci · 2018 · European Journal of Nuclear Medicine and Molecular Imaging
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
Shengjie Tang, Chao Qin, Haiyang Hu, Tao Liu, Yiwei He, Haiyang Guo, Hang Yan, Jun Zhang, Shoujun Tang, Haining Zhou · 2022 · Cells
The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer
Yu Fujita, Shigehiro Yagishita, Keitaro Hagiwara, Yusuke Yoshioka, Nobuyoshi Kosaka, Fumitaka Takeshita, Tomohiro Fujiwara, Koji Tsuta, Hiroshi Nokihara, Tomohide Tamura et al. · 2015 · Molecular Therapy
Patterns of Response and Progression to Immunotherapy
Édith Borcoman, Amara Gayathri Nandikolla, Georgina Venetia Long, Sanjay Goel, Christophe Le Tourneau · 2018 · American Society of Clinical Oncology Educational Book
Second- and third-generation drugs for immuno-oncology treatment—The more the better?
Wolfram C. M. Dempke, Klaus Fenchel, Peter Uciechowski, Stephen P. Dale · 2017 · European Journal of Cancer